ISAC. Whole Allergens. Allergen Components. Phadiatop & Phadiatop Infant. Molecular Allergology. EliA Assays. Phadia Laboratory Systems. ImmunoCAP. ImmunoCAP ISAC®. Immuno Solid-phase Allergen Chip. VBC Genomics and Phadia have combined innovative biochip technology with cutting-edge research . The immuno-solid phase allergen chip (ISAC) enables testing for . ImmunoCAP tests were done on the Thermofisher Phadia platform.
|Country:||Saint Kitts and Nevis|
|Published (Last):||12 June 2007|
|PDF File Size:||18.26 Mb|
|ePub File Size:||1.80 Mb|
|Price:||Free* [*Free Regsitration Required]|
Detailed cost analyses suggested that multiplex allergen testing would have to result in a substantial reduction of the padia of patients receiving single IgE testing and oral food challenge tests in order to be cost-saving in the short term. Allergy is a form of immune-mediated exaggerated sensitivity hypersensitivity to a substance that is either inhaled, swallowed, injected or comes into contact with the skin.
ImmunoCAP ISAC Multiplexing – Phadia – Setting the Standard –
This is especially true when symptoms and case history are inconsistent, the patient is multi-sensitized or shows unsatisfactory response to the treatment. Owing to a lack of data on the clinical effectiveness of multiplex allergen testing, no long-term cost-effectiveness model was developed.
All trademarks are the property of Thermo Fisher Scientific Inc. The methodological quality of included studies was assessed using appropriate published tools or a review-specific tool designed by the project phxdia.
ImmunoCAP ISAC – When you need the bigger picture in allergy
ImmunoCAP ISAC — When you need the bigger picture in allergy Trying to find the original cause for allergic reactions can sometimes feel like looking for a needle in a haystack.
Phadia AB, Uppsala, Sweden.
It is suggested that a consensus-based protocol for the use of multiplex allergen testing be developed. The clinical effectiveness and cost-effectiveness of the proposed protocol should then be assessed by comparing long-term clinical and quality of life outcomes and resource use in patients managed using the protocol with those managed using a standard diagnostic pathway.
There was some indication that the use of ImmunoCAP ISAC testing may be useful to guide decisions on the discontinuation of restrictive diets, the content of allergen-specific immunotherapy SIT prescriptions, and whether or not patients should receive SIT.
However, none of the studies that we identified reported any information on clinical outcomes subsequent to changes in treatment or management. Helping scientists meet the challenges they face in the lab or in the field every day.
Studies were summarised in a narrative synthesis. As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.
ImmunoCAP ISAC – Phadia – Setting the Standard –
Foreign substances that provoke allergies are called allergens. To evaluate multiplex allergen testing [devices that can measure the presence of multiple immunoglobulin E IgE antibodies in a patient’s blood at the same time], by assessing 1 clinical effectiveness allergy symptoms, incidence of acute exacerbations, mortality, adverse events of testing and treatment, health-care presentations or admissions, health-related quality of life ; 2 effects on treatment diet, immunotherapy medications, other potential testing ; 3 any additional diagnostic information provided by multiplex allergen testing; and 4 cost-effectiveness cost of different assessment strategies.
No recommendations for service provision can be made based on the analyses included in this report. Fifteen studies were included in the review. This advanced technology enables measurement of IgE antibodies to a fixed panel of components from 51 allergen sources in a single step, using only 30 ul of serum or plasma.
It has been claimed that multiplex allergen testing may help in diagnosing the cause of symptoms in patients with an unclear cause of allergy or who are allergic to more than one substance. It is the result of a combination of innovative biochip technology and cutting edge research in molecular allergology.
A conceptual model structure was developed and cost analyses were performed to examine the short-term costs of various possible diagnostic pathways. ImmunoCAP ISAC is the first multiplex in vitro diagnostic tool for the allergy specialist that is based exclusively on allergen components.